CERS: Revenue rose 10%, adjusted EBITDA stayed positive, and RedeS met its primary efficacy endpoint

What happened

In the third quarter, product revenue rose 10% from a year earlier. Adjusted EBITDA, a profit measure before certain costs, was positive for a 10th straight quarter, and operating cash flow was $3 million. RedeS met its main efficacy goal, and full-year 2026 product revenue guidance was reaffirmed at $229 million to $231 million.

Confirmed

Global impact / market context

Positive adjusted EBITDA and $3 million of operating cash flow mean the company is generating cash from its core operations rather than only reporting accounting revenue. Reaffirmed 2026 product revenue guidance of $229 million to $231 million gives investors a stated target to compare against future quarterly sales.

Analyst inference

Revenue growing 10% while adjusted EBITDA stays positive points to sales expanding faster than the costs excluded from that measure, though the article does not give expense figures. Meeting the RedeS efficacy goal supports the product's clinical path but does not by itself confirm regulatory approval or future revenue.

Analyst inference

What to watch

1. Watch whether full-year 2026 product revenue lands within the reaffirmed $229 million to $231 million range, since that guidance is the company's own stated target for future sales. Confirmed
2. Track whether adjusted EBITDA remains positive in coming quarters, which would show the company can keep covering its operating costs without relying on outside funding. Proposed
3. Follow RedeS through later testing and regulatory steps, because meeting a primary efficacy endpoint is an early result and does not guarantee approval or commercial sales. Analyst inference

Evidence

• Original source link unavailable